Lixiana

How to order Lixiana

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Lixiana on Prescriptsy

Lixiana is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Lixiana is the brand name for edoxaban, a prescription-only direct oral anticoagulant (DOAC) used to prevent stroke in adults with non-valvular atrial fibrillation and to treat and prevent recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE).

Edoxaban belongs to the class of direct factor Xa inhibitors, which also includes rivaroxaban and apixaban.

It works by directly and selectively blocking factor Xa, a key enzyme in the blood clotting cascade, reducing the formation of harmful blood clots.

Lixiana is taken once daily as a fixed-dose tablet, does not require routine coagulation monitoring (unlike warfarin), and has fewer dietary restrictions and drug interactions than vitamin K antagonists.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the United Kingdom, affecting an estimated 1.5 million people.

In AF, the upper chambers of the heart (the atria) beat irregularly and often rapidly, which allows blood to pool and form clots.

If a clot travels to the brain, it causes an ischaemic stroke.

AF-related strokes tend to be more severe and more likely to result in disability or death than strokes from other causes.

Anticoagulation therapy reduces the risk of stroke in AF by approximately 60 to 70%.

Venous thromboembolism (VTE), comprising DVT and PE, is another major thrombotic condition, with an estimated annual incidence of approximately 1 in 1,000 people.

This page provides a comprehensive clinical guide to Lixiana, covering how edoxaban works, its clinical evidence base, dosage, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Lixiana

Before reading further, note these essential safety points.

• Lixiana is a prescription-only anticoagulant that increases the risk of bleeding.
• Carry your anticoagulant alert card at all times.
• Do not stop taking Lixiana without consulting your prescriber, as this increases the risk of stroke or blood clots.
• Tell all healthcare professionals (including dentists and pharmacists) that you take edoxaban.
• Seek immediate medical help if you experience signs of serious bleeding or stroke.

Understanding atrial fibrillation and stroke risk

Atrial fibrillation causes the atria to contract irregularly, disrupting the normal flow of blood. This stasis allows clots to form, particularly in the left atrial appendage.

If a clot is dislodged, it can travel through the circulation and block a cerebral artery, causing an ischaemic stroke.

The risk of stroke in AF is assessed using the CHA2DS2-VASc score, which assigns points for congestive heart failure, hypertension, age 75 or over (2 points), diabetes, prior stroke or TIA (2 points), vascular disease, age 65 to 74, and female sex.

NICE guideline NG196 recommends anticoagulation for men with a CHA2DS2-VASc score of 2 or more and women with a score of 3 or more.

Anticoagulation should also be considered for men with a score of 1 and women with a score of 2.

NICE recommends DOACs (including edoxaban) in preference to warfarin for most patients with AF requiring anticoagulation, based on their favourable balance of efficacy, safety, and convenience.

DOACs have a predictable dose-response relationship, fewer food and drug interactions, and do not require routine INR monitoring.

Understanding venous thromboembolism

Deep vein thrombosis occurs when a blood clot forms in a deep vein, most commonly in the leg. Symptoms include leg swelling, pain, warmth, and redness.

Pulmonary embolism occurs when part or all of the clot breaks off and travels to the lungs, causing chest pain, breathlessness, and, in severe cases, cardiovascular collapse.

VTE risk factors include surgery, immobility, cancer, obesity, pregnancy, combined oral contraceptives, long-haul travel, and inherited thrombophilia.

Anticoagulation is the cornerstone of VTE treatment, preventing clot extension and recurrence while the body's own fibrinolytic system gradually dissolves the existing clot.

How edoxaban works: mechanism of action

The coagulation cascade is a series of enzymatic reactions that culminate in the formation of a fibrin clot.

Factor Xa sits at a critical junction in this cascade, converting prothrombin (factor II) to thrombin (factor IIa), which then converts fibrinogen to fibrin.

Edoxaban directly and reversibly inhibits free factor Xa and prothrombinase activity, reducing thrombin generation and clot formation.

By targeting a single point in the cascade, edoxaban provides predictable anticoagulation without affecting upstream or downstream factors directly.

Edoxaban is rapidly absorbed after oral administration, reaching peak plasma levels within 1 to 2 hours. Its oral bioavailability is approximately 62%.

It has a half-life of 10 to 14 hours, supporting once-daily dosing.

Approximately 50% of the absorbed dose is excreted unchanged by the kidneys, and the remainder is metabolised by the liver via hydrolysis, conjugation, and CYP3A4 oxidation.

This dual elimination pathway means that both renal and hepatic function affect edoxaban exposure.

Clinical evidence for edoxaban

The ENGAGE AF-TIMI 48 trial, a large randomised controlled trial involving 21,105 patients with atrial fibrillation, compared edoxaban 60 mg (or 30 mg in dose-reduced patients) with warfarin over a median follow-up of 2.8 years.

Edoxaban was non-inferior to warfarin for the prevention of stroke and systemic embolism and was associated with significantly lower rates of major bleeding (2.75% per year vs 3.43%), intracranial haemorrhage, and cardiovascular mortality.

The Hokusai-VTE trial, involving 8,292 patients with acute VTE, demonstrated that edoxaban was non-inferior to warfarin for the prevention of recurrent VTE, with a lower rate of clinically relevant bleeding.

NICE technology appraisal TA354 recommends edoxaban as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation. NICE TA354 also recommends edoxaban for treating and preventing recurrent DVT and PE.

Edoxaban compared with other DOACs and warfarin

Four DOACs are available in the UK: edoxaban (Lixiana), rivaroxaban (Xarelto), apixaban (Eliquis), and dabigatran (Pradaxa).

Edoxaban and rivaroxaban are taken once daily, while apixaban is taken twice daily and dabigatran is taken twice daily.

Direct head-to-head trials between DOACs are limited, and each has been shown to be at least as effective as warfarin with a lower risk of major bleeding.

The choice between DOACs often depends on dosing preference, renal function, drug interactions, and formulary availability.

Warfarin remains an option for patients who prefer it, who have mechanical heart valves (where DOACs are contraindicated), or where cost is a consideration.

However, warfarin requires regular INR monitoring, has numerous food and drug interactions, and has a narrow therapeutic window.

Most new anticoagulant initiations in the UK are now DOACs rather than warfarin.

Dosage and administration

The standard dose is 60 mg once daily.

Dose reduction to 30 mg is required for patients with creatinine clearance 15 to 50 mL/min, body weight 60 kg or below, or concomitant use of specified P-glycoprotein inhibitors.

For VTE treatment, Lixiana must be preceded by at least 5 days of parenteral anticoagulation. Treatment duration depends on the clinical context and ongoing risk assessment.

Side effects of edoxaban

Bleeding

Bleeding is the principal risk. Minor bleeding (bruising, nosebleeds, gum bleeding) is common. Serious bleeding events, including gastrointestinal and intracranial haemorrhage, are less common but can be life-threatening.

The ENGAGE AF-TIMI 48 trial showed significantly lower major bleeding rates with edoxaban compared with warfarin.

Other side effects

Nausea, rash, abnormal liver function tests, anaemia, abdominal pain, and headache are reported. Allergic reactions (urticaria, pruritus, angioedema) are uncommon.

When to seek urgent medical advice

Contact your GP or call NHS 111 for unusual bruising, nosebleeds lasting more than 10 minutes, or blood in your urine.

Call 999 or attend A&E for vomiting blood, black tarry stools, sudden severe headache, sudden weakness or numbness, visual disturbance, coughing up blood, or signs of a severe allergic reaction.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Lixiana must not be used in patients with active significant bleeding, liver disease with coagulopathy, uncontrolled severe hypertension, conditions with a major risk of major bleeding, or known hypersensitivity.

It must not be used if creatinine clearance is below 15 mL/min or (in AF patients) above 95 mL/min.

Surgery and procedures

Stop Lixiana at least 24 hours before elective surgery. For high-bleeding-risk procedures, a longer washout period may be needed. Carry your anticoagulant alert card at all times.

Drug interactions

P-glycoprotein inhibitors (ciclosporin, dronedarone, erythromycin, ketoconazole) increase edoxaban levels and require dose reduction. Antiplatelet agents, NSAIDs, and other anticoagulants increase bleeding risk. Rifampicin reduces edoxaban efficacy. Inform all healthcare professionals of your medication.

Pregnancy and breastfeeding

Lixiana is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception.

How to get Lixiana in the UK

Lixiana is a prescription-only medicine.

Your GP, cardiologist, or authorised online prescriber registered with the General Pharmaceutical Council (GPhC) can prescribe it after a clinical assessment including AF diagnosis or VTE confirmation, renal function testing, and bleeding risk evaluation.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living with anticoagulation

Taking an anticoagulant requires awareness of bleeding risk in daily life. Use a soft toothbrush and an electric razor to reduce minor bleeding.

Take care with sharp objects and contact sports. Carry your anticoagulant alert card at all times.

Tell all healthcare providers, including dentists, physiotherapists, and podiatrists, that you take edoxaban. Wear a medical alert bracelet if you wish.

Report any falls, particularly head injuries, to your GP or attend A&E, as intracranial bleeding may not produce immediate symptoms.

Do not stop taking Lixiana without medical advice, as interruption of anticoagulation significantly increases the risk of stroke or recurrent VTE.

Travel considerations are important for patients on anticoagulation.

If you are flying long-haul, stay well hydrated, perform calf exercises regularly during the flight, and consider wearing compression stockings to reduce the risk of DVT.

Carry your medication in your hand luggage along with a copy of your prescription and your anticoagulant alert card.

Ensure you have enough supply for the entire trip plus extra in case of delays.

If you are travelling to a different time zone, take your dose at the equivalent local time and maintain the 24-hour interval between doses.

Check that your travel insurance covers your medical condition and anticoagulant therapy.

Dietary considerations are less restrictive with edoxaban than with warfarin. Warfarin interacts significantly with vitamin K-rich foods (green leafy vegetables, liver, certain oils), requiring consistent dietary intake.

Edoxaban does not interact with vitamin K, so there are no specific dietary restrictions. You may eat a normal, varied diet.

However, excessive alcohol consumption should be avoided, as it increases the risk of gastrointestinal bleeding and can impair liver function.

Sources

• Lixiana Film-Coated Tablets, Summary of Product Characteristics (EMC)
• Edoxaban, British National Formulary (BNF)
• NICE TA354: Edoxaban for treating and preventing DVT and PE
• NICE NG196: Atrial fibrillation: diagnosis and management
• Edoxaban, NHS medicines information
• MHRA Yellow Card Scheme